1092 related articles for article (PubMed ID: 32882868)
1. Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2.
Muchtaridi M; Fauzi M; Khairul Ikram NK; Mohd Gazzali A; Wahab HA
Molecules; 2020 Sep; 25(17):. PubMed ID: 32882868
[TBL] [Abstract][Full Text] [Related]
2. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
Cheng H; Wang Y; Wang GQ
J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
[TBL] [Abstract][Full Text] [Related]
3. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
Choudhary S; Silakari O
Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
[TBL] [Abstract][Full Text] [Related]
4. Discovery and characterization of ACE2 - a 20-year journey of surprises from vasopeptidase to COVID-19.
Hooper NM; Lambert DW; Turner AJ
Clin Sci (Lond); 2020 Sep; 134(18):2489-2501. PubMed ID: 32990314
[TBL] [Abstract][Full Text] [Related]
5. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor.
Li Y; Zhou W; Yang L; You R
Pharmacol Res; 2020 Jul; 157():104833. PubMed ID: 32302706
[TBL] [Abstract][Full Text] [Related]
6. Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.
Brojakowska A; Narula J; Shimony R; Bander J
J Am Coll Cardiol; 2020 Jun; 75(24):3085-3095. PubMed ID: 32305401
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the genetic variation in ACE2 on the structural recognition by the novel coronavirus (SARS-CoV-2).
Guo X; Chen Z; Xia Y; Lin W; Li H
J Transl Med; 2020 Aug; 18(1):321. PubMed ID: 32831104
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).
Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H
J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.
Buckley LF; Cheng JWM; Desai A
J Cardiovasc Pharmacol; 2020 Jun; 75(6):526-529. PubMed ID: 32301766
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
Datta PK; Liu F; Fischer T; Rappaport J; Qin X
Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
[TBL] [Abstract][Full Text] [Related]
11. Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists.
Steckelings UM; Sumners C
Clin Sci (Lond); 2020 Nov; 134(22):2987-3006. PubMed ID: 33210709
[TBL] [Abstract][Full Text] [Related]
12. Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2).
Zemlin AE; Wiese OJ
Ann Clin Biochem; 2020 Sep; 57(5):339-350. PubMed ID: 32369402
[TBL] [Abstract][Full Text] [Related]
13. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 host tropism: An in silico analysis of the main cellular factors.
Rangel HR; Ortega JT; Maksoud S; Pujol FH; Serrano ML
Virus Res; 2020 Nov; 289():198154. PubMed ID: 32918944
[TBL] [Abstract][Full Text] [Related]
15. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.
Hanke L; Vidakovics Perez L; Sheward DJ; Das H; Schulte T; Moliner-Morro A; Corcoran M; Achour A; Karlsson Hedestam GB; Hällberg BM; Murrell B; McInerney GM
Nat Commun; 2020 Sep; 11(1):4420. PubMed ID: 32887876
[TBL] [Abstract][Full Text] [Related]
16. ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV.
Lubbe L; Cozier GE; Oosthuizen D; Acharya KR; Sturrock ED
Clin Sci (Lond); 2020 Nov; 134(21):2851-2871. PubMed ID: 33146371
[TBL] [Abstract][Full Text] [Related]
17. Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment.
Teralı K; Baddal B; Gülcan HO
J Mol Graph Model; 2020 Nov; 100():107697. PubMed ID: 32739642
[TBL] [Abstract][Full Text] [Related]
18. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
19. A protein interaction map identifies existing drugs targeting SARS-CoV-2.
Cava C; Bertoli G; Castiglioni I
BMC Pharmacol Toxicol; 2020 Sep; 21(1):65. PubMed ID: 32883368
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 and the possible connection to ERs, ACE2, and RAGE: Focus on susceptibility factors.
Stilhano RS; Costa AJ; Nishino MS; Shams S; Bartolomeo CS; Breithaupt-Faloppa AC; Silva EA; Ramirez AL; Prado CM; Ureshino RP
FASEB J; 2020 Nov; 34(11):14103-14119. PubMed ID: 32965736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
